Literature DB >> 33119090

Different left ventricular remodelling patterns and clinical outcomes between non-ischaemic and ischaemic aetiologies in heart failure patients receiving sacubitril/valsartan treatment.

Ying-Hsiang Lee1,2, Wei-Ru Chiou2,3, Chien-Yi Hsu4,5, Po-Lin Lin2,6, Huai-Wen Liang7, Fa-Po Chung4,8, Chia-Te Liao9, Wen-Yu Lin10, Hung-Yu Chang4,11.   

Abstract

AIMS: Although the beneficial effect of sacubitril/valsartan (SAC/VAL) compared to enalapril was consistent across ischaemic cardiomyopathy (ICM) and non-ischaemic cardiomyopathy (NICM) groups, the PARADIGM-HF study did not analyse the effect of ventricular remodelling on patients with different aetiologies, which may affect clinical treatment outcomes. This study aimed to compare left ventricular ejection fraction (LVEF) following SAC/VAL treatment and its association with clinical outcomes. METHODS AND
RESULTS: A total of 1576 patients were analysed. Patients were grouped by LVEF changes following SAC/VAL treatment for 8-month period. LVEF improvement ≥15% was defined as 'significant improvement', and <5% or worse was classified as 'lack of improvement'. The primary outcome was a composite of cardiovascular death and unplanned hospitalization for heart failure. Patients with NICM had lower baseline LVEF but improvement was significantly greater comparing to those with ICM (baseline 28.0 ± 7.7% vs. 30.1 ± 7.1%, P < 0.001, LVEF increase of 11.1 ± 12.6% vs. 6.7 ± 10.2%, P < 0.001). The effect of functional improvement of SAC/VAL on NICM patients showed bimodal distribution. Primary endpoints were inversely associated with LVEF changes in NICM patients: adjusted hazard ratio was 0.42 [95% confidence interval (CI) 0.31-0.58, P < 0.001] for NICM patients with significant improvement, and was 1.73 (95% CI 1.38-2.16, P < 0.001) for NICM patients but lack of improvement. Primary endpoints of ICM patients did not demonstrate an association with LVEF changes.
CONCLUSION: Patients with NICM had higher degree of LVEF improvement than those with ICM following SAC/VAL treatment, and significant improvement of LVEF in NICM patients indicates favourable outcome. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2020. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Aetiology; Heart failure; Left ventricular ejection fraction; Reverse remodelling; Sacubitril/valsartan

Mesh:

Substances:

Year:  2022        PMID: 33119090     DOI: 10.1093/ehjcvp/pvaa125

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Pharmacother


  10 in total

Review 1.  Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction.

Authors:  Michele Correale; Pietro Mazzeo; Lucia Tricarico; Francesca Croella; Martino Fortunato; Michele Magnesa; Marco Amatruda; Simona Alfieri; Salvatore Ferrara; Vincenzo Ceci; Giuseppe Dattilo; Marco Mele; Massimo Iacoviello; Natale Daniele Brunetti
Journal:  Clin Drug Investig       Date:  2022-06-20       Impact factor: 2.859

2.  A Heart Team approach to contemporary device decision-making in heart failure.

Authors:  Anubodh S Varshney; Jagmeet P Singh; Muthiah Vaduganathan
Journal:  Eur J Heart Fail       Date:  2022-02-13       Impact factor: 15.534

Review 3.  Pleiotropic Properties of Valsartan: Do They Result from the Antiglycooxidant Activity? Literature Review and In Vitro Study.

Authors:  Kacper Maksymilian Mil; Małgorzata Ewa Gryciuk; Cezary Pawlukianiec; Małgorzata Żendzian-Piotrowska; Jerzy Robert Ładny; Anna Zalewska; Mateusz Maciejczyk
Journal:  Oxid Med Cell Longev       Date:  2021-03-03       Impact factor: 6.543

4.  Catheter Ablation for Atrial Fibrillation Targeting Incremental Left Ventricular Ejection Fraction - Reply.

Authors:  Kyoichiro Yazaki; Koichiro Ejima; Shohei Kataoka; Daigo Yagishita; Morio Shoda; Nobuhisa Hagiwara
Journal:  Circ Rep       Date:  2021-04-24

5.  Sacubitril/Valsartan to Treat Heart Failure in a Patient with Relapsing Hairy Cell Leukaemia: Case Report.

Authors:  Alessandro Lupi; Sara Ariotti; Doranna De Pace; Irene Ferrari; Stefano Bertuol; Lorenzo Monti; Luigina Guasti; Giovanni Vincenzo Gaudio; Carlo Campana
Journal:  Clin Med Insights Cardiol       Date:  2021-04-13

6.  Characterization of heart failure patients with reverse left ventricular remodelling post-angiotensin receptor blockers/neprilysin inhibitors therapy.

Authors:  Leonid Maizels; Yishay Wasserstrum; Boris Fishman; Amitai Segev; David Ben-Nun; Anan Younis; Dov Freimark; Israel Mazin; Avishay Grupper
Journal:  ESC Heart Fail       Date:  2022-02-18

7.  Utility of PREDICT-HF score in high-risk Asian heart failure patients receiving sacubitril/valsartan.

Authors:  Chien-Yi Hsu; Hung-Yu Chang; Chieh-Ju Chao; Wei-Ru Chiou; Po-Lin Lin; Fa-Po Chung; Wen-Yu Lin; Jin-Long Huang; Huai-Wen Liang; Chia-Te Liao; Ying-Hsiang Lee
Journal:  Front Cardiovasc Med       Date:  2022-07-25

8.  Levosimendan Administration May Provide More Benefit for Survival in Patients with Non-Ischemic Cardiomyopathy Experiencing Acute Decompensated Heart Failure.

Authors:  Wei-Chieh Lee; Po-Jui Wu; Hsiu-Yu Fang; Yen-Nan Fang; Huang-Chung Chen; Meng-Shen Tong; Pei-Hsun Sung; Chieh-Ho Lee; Wen-Jung Chung
Journal:  J Clin Med       Date:  2022-07-10       Impact factor: 4.964

9.  Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.

Authors:  James P Curtain; Alice M Jackson; Li Shen; Pardeep S Jhund; Kieran F Docherty; Mark C Petrie; Davide Castagno; Akshay S Desai; Luis E Rohde; Martin P Lefkowitz; Jean-Lucien Rouleau; Michael R Zile; Scott D Solomon; Karl Swedberg; Milton Packer; John J V McMurray
Journal:  Eur J Heart Fail       Date:  2022-01-19       Impact factor: 17.349

10.  Delayed Improvement of Left Ventricular Function in Newly Diagnosed Heart Failure Depends on Etiology-A PROLONG-II Substudy.

Authors:  Johanna Mueller-Leisse; Johanna Brunn; Christos Zormpas; Stephan Hohmann; Henrike Aenne Katrin Hillmann; Jörg Eiringhaus; Johann Bauersachs; Christian Veltmann; David Duncker
Journal:  Sensors (Basel)       Date:  2022-03-05       Impact factor: 3.576

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.